Navidea Biopharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | $1.58 | $1.58 | $1.58 |
| Q2 2024 | 1 | $1.34 | $1.34 | $1.34 |
| Q3 2024 | 1 | $1.54 | $1.54 | $1.54 |
Navidea Biopharmaceuticals, Inc. Earnings Date And Information
Navidea Biopharmaceuticals, Inc. last posted its earnings results on Wednesday, November 10th, 2021. The company reported $-0.08 earnings per share for the quarter, topping analysts' consensus estimates of $-0.11 by $0.03. The company had revenue of 0 for the quarter and had revenue of 65,652 for the year. Navidea Biopharmaceuticals, Inc. has generated $-1 earnings per share over the last year ($-0.59 diluted earnings per share) and currently has a price-to-earnings ratio of 0.01. Navidea Biopharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based on prior year's report dates.
Navidea Biopharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2023 | Q3 2023 | -$0.02 | $0 | $0 | ||
| 08/11/2023 | Q2 2023 | $0.12 | $0 | |||
| 05/11/2023 | Q1 2023 | -$0.02 | $0 | |||
| 03/27/2023 | Q4 2022 | -$0.17 | $610 | |||
| 11/14/2022 | Q3 2022 | -$0.19 | $7,516 | |||
| 08/15/2022 | Q2 2022 | -$0.10 | $6,519 | |||
| 05/16/2022 | Q1 2022 | -$0.10 | $0 | |||
| 03/28/2022 | Q4 2021 | -$0.12 | $50,348 | |||
| 11/12/2021 | Q3 2021 | -$0.08 | $600,000 | $96,382 | ||
| 08/12/2021 | Q2 2021 | -$0.09 | $600,000 | $261,046 | ||
| 05/13/2021 | Q1 2021 | -$0.11 | $123,737 | |||
| 03/26/2021 | Q4 2020 | -$0.11 | $219,251 | |||
| 11/13/2020 | Q3 2020 | -$0.11 | $300,000 | $6,773 | ||
| 08/14/2020 | Q2 2020 | -$0.10 | $600,000 | $8,920 | ||
| 05/15/2020 | Q1 2020 | -$0.13 | $15,221 | |||
| 03/18/2020 | Q4 2019 | -$0.15 | $2,680 | |||
| 11/08/2019 | Q3 2019 | -$0.17 | $4,895 | |||
| 08/09/2019 | Q2 2019 | -$0.24 | $162,557 | $15,893 | ||
| 05/09/2019 | Q1 2019 | -$0.24 | $97,558 | |||
| 03/15/2019 | Q4 2018 | -$0.33 | $35,040 |
Navidea Biopharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Navidea Biopharmaceuticals, Inc.'s earnings date?
Navidea Biopharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off last year's report dates.
-
Did Navidea Biopharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Navidea Biopharmaceuticals, Inc. (:NAVB) reported $-0.08 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.11 by $0.03.
-
How can I listen to Navidea Biopharmaceuticals, Inc.'s earnings conference call?
The conference call for Navidea Biopharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Navidea Biopharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Navidea Biopharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Navidea Biopharmaceuticals, Inc. generate each year?
Navidea Biopharmaceuticals, Inc. (:NAVB) has a recorded annual revenue of $65,652.
-
How much profit does Navidea Biopharmaceuticals, Inc. generate each year?
Navidea Biopharmaceuticals, Inc. (:NAVB) has a recorded net income of $65,652. Navidea Biopharmaceuticals, Inc. has generated $-0.59 earnings per share over the last four quarters.
-
What is Navidea Biopharmaceuticals, Inc.'s price-to-earnings ratio?
Navidea Biopharmaceuticals, Inc. (:NAVB) has a price-to-earnings ratio of 0.01 and price/earnings-to-growth ratio is 0.
